Assessment and uptake of hepatitis C treatment among injection drug users with HCV infection remains low, partly due to concerns regarding poor adherence and response to therapy. Findings from a large, prospective study demonstrate comparable adherence and response to hepatitis C treatment among nondrug users, former drug users and active drug users.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Shepard, C. W., Finelli, L. & Alter, M. J. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 5, 558–567 (2005).
Manns, M. P., Wedemeyer, H. & Cornberg, M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55, 1350–1359 (2006).
NIH. National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology 26, 2S–10S (1997).
Sylvestre, D. L. Treating hepatitis C in methadone maintenance patients: an interim analysis. Drug Alcohol Depend. 67, 117–123 (2002).
Backmund, M., Meyer, K., Von Zielonka, M. & Eichenlaub, D. Treatment of hepatitis C infection in injection drug users. Hepatology 34, 188–193 (2001).
NIH. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens. State Sci. Statements 19, 1–46 (2002).
Grebely, J., deVlaming, S., Duncan, F., Viljoen, M. & Conway, B. Current approaches to HCV infection in current and former injection drug users. J. Addict. Dis. 27, 25–35 (2008).
Melin, P. et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur. J. Gastroenterol. Hepatol. 22, 1050–1057 (2010).
Hellard, M., Sacks-Davis, R. & Gold, J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin. Infect. Dis. 49, 561–573 (2009).
Grebely, J. et al. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend. 93, 141–147 (2008).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
G. Dore has received research support, is on the speaker's bureau and is a member of an advisory board for Roche Pharmaceuticals. He is also a Consultant/Advisor for Abbott, Merck, and Tibotec. J. Grebely is a member of an advisory board for Schering-Plough.
Rights and permissions
About this article
Cite this article
Grebely, J., Dore, G. Enhancing treatment for hepatitis C among drug users. Nat Rev Gastroenterol Hepatol 8, 11–13 (2011). https://doi.org/10.1038/nrgastro.2010.186
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2010.186
This article is cited by
-
High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening
Infection (2016)
-
Label-free sandwich type of immunosensor for hepatitis C virus core antigen based on the use of gold nanoparticles on a nanostructured metal oxide surface
Microchimica Acta (2012)